An American research study revealed a hospital Mount Sinai New York for the success of a drug evinacumab Experimental reduction in low-density lipoprotein cholesterol, or the so-called “bad” cholesterol, by 50% in patients with severe hypercholesterolemia, whose condition is resistant to standard treatments, according to a newspaper. TIME NOW NEWS .
The results of the study were presented in scientific sessions of the American Heart Association and simultaneously published in a journal New England Journal of Medicine.
Evinacumab It is an entirely human monoclonal antibody that works through a different mechanism from current medications to bring dangerously high levels of cholesterol to normal levels, when combined with lipid-lowering therapies tolerated by people with familial hypercholesterolemia, a common genetic condition that is difficult to treat.
Said lead investigator Robert Rosenson, professor of cardiology and director of cardiovascular disorders at the School of Medicine Mount Sinaik This drug is a completely human monoclonal antibody that lowers harmful cholesterol.
The second phase of the multi-center study involved 272 patients with primary hypercholesterolemia, including the majority of them diagnosed with familial hypercholesterolemia, an inherited form of hypercholesterolemia that is often caused by mutations in the receptor gene. LDLThe research team found that subcutaneous administration of the antibody component at a dose of 450 mg per week reduced LDL cholesterol by 56%, and 52.9% at an average of 300 mg per week compared to the placebo group..
With giving evinacumab Monthly intravenous administration at 15 mg / kg, LDL cholesterol reduction was 50.5% compared to the placebo group. All patients treated with ivinacumab were on basic lipid-lowering treatments.
– .
